Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 49, 5523-5529, October 15, 1989]
© 1989 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mirzayans, R.
Right arrow Articles by Paterson, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mirzayans, R.
Right arrow Articles by Paterson, M. C.

Hypersensitivity to Cell Killing and Faulty Repair of 1-ß-D-Arabinofuranosylcytosine-detectable Sites in Human (Ataxia-Telangiectasia) Fibroblasts Treated with 4-Nitroquinoline 1-Oxide1

Razmik Mirzayans, Blake P. Smith and Malcolm C. Paterson2

Molecular Genetics and Carcinogenesis Laboratory, Cross Cancer Institute, Edmonton, Alberta T6G 1Z2 [R. M., M. C. P.], and the Health Sciences Division, Chalk River Nuclear Laboratories, Chalk River, Ontario K0J 1J0 [B. P. S.], Canada

Dermal fibroblast strains from ataxia-telangiectasia (A–T) patients and clinically normal subjects were exposed to 4-nitroquinoline 1-oxide (4NQO) or its 3-methyl derivative (3me4NQO), and their colony-forming abilities and DNA metabolic properties were compared. Three A–T strains, i.e., AT2BE and AT3BI representing genetic complementation group AB and AT4BI belonging to group C, displayed enhanced (2.4- to 2.8-fold) sensitivity to reproductive inactivation by 4NQO, but exhibited normal survival in response to 3me4NQO. The initial induction and subsequent enzymatic repair of alkali-labile lesions (i.e., damaged sites converted to single-strand breaks in alkali) were quantitated by conventional velocity sedimentation analysis of cellular DNA in alkaline sucrose gradients. On exposure to concentrations of each chemical that produced comparable amounts of DNA damage, A–T and normal cells removed alkali-labile lesions at similar rates. However, the three 4NQO-sensitive A–T strains appeared to be defective in acting on alkali-stable adducts (formed by the parent compound but not its derivative), as judged by strand-break accumulation during posttreatment incubation with 1-ß-D-arabinofuranosylcytosine (araC). Specifically, the number of araC-detectable sites repaired in these A–T strains during the critical 2-h period immediately following 4NQO treatment ranged from 40 to 60% of that processed by normal controls. AT5BI, a fourth A–T strain assigned to complementation group D, responded normally to 4NQO-induced cytotoxicity and removed both alkali-labile and alkali-stable (araC-detectable) lesions normally. We thus conclude that the hypersensitivity of AT2BE, AT3BI, and AT4BI strains to 4NQO may be attributed, at least in part, to faulty execution of the excision-repair process operative on alkali-stable 4NQO adducts.

1 Supported initially by Atomic Energy of Canada Limited and the U. S. National Cancer Institute through Contract NO1-CP-21029 (Basic) with the Clinical and Environmental Epidemiology Branches, Bethesda, MD, and in the later stages by research grants from the National Cancer Institute of Canada and the Ataxia-Telangiectasia Medical Research Foundation and by Medical Scientist (M. C. P.) and Postdoctoral Fellowship (R. M.) awards from the Alberta Heritage Foundation for Medical Research.

2 To whom requests for reprints should be addressed, at Molecular Genetics and Carcinogensis Laboratory, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada.

Received 3/30/88. Revised 12/12/88. Revised 7/ 5/89. Accepted 7/ 6/89.




This article has been cited by other articles:


Home page
Toxicol SciHome page
Y. Arima, C. Nishigori, T. Takeuchi, S. Oka, K. Morimoto, A. Utani, and Y. Miyachi
4-Nitroquinoline 1-Oxide Forms 8-Hydroxydeoxyguanosine in Human Fibroblasts through Reactive Oxygen Species
Toxicol. Sci., June 1, 2006; 91(2): 382 - 392.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
E. Fritz, A. A. Friedl, R. M. Zwacka, F. Eckardt-Schupp, and M. S. Meyn
The Yeast TEL1 Gene Partially Substitutes for Human ATM in Suppressing Hyperrecombination, Radiation-Induced Apoptosis and Telomere Shortening in A-T Cells
Mol. Biol. Cell, August 1, 2000; 11(8): 2605 - 2616.
[Abstract] [Full Text]


Home page
CarcinogenesisHome page
R. Mirzayans, S. Bashir, D. Murray, and M. C. Paterson
Inverse correlation between p53 protein levels and DNA repair efficiency in human fibroblast strains treated with 4-nitroquinoline 1-oxide: evidence that lesions other than DNA strand breaks trigger the p53 response
Carcinogenesis, June 1, 1999; 20(6): 941 - 946.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Heron-Milhavet, M. Karas, C. M. Goldsmith, B. J. Baum, and D. LeRoith
Insulin-like Growth Factor-I (IGF-I) Receptor Activation Rescues UV-damaged Cells through a p38 Signaling Pathway. POTENTIAL ROLE OF THE IGF-I RECEPTOR IN DNA REPAIR
J. Biol. Chem., May 18, 2001; 276(21): 18185 - 18192.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1989 by the American Association for Cancer Research.